Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59,746,870
-
Total 13F shares
-
48,318,843
-
Share change
-
+3,854,076
-
Total reported value
-
$1,129,194,355
-
Put/Call ratio
-
4.9%
-
Price per share
-
$23.37
-
Number of holders
-
91
-
Value change
-
+$91,652,714
-
Number of buys
-
65
-
Number of sells
-
26
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q2 2024
As of 30 Jun 2024,
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) was held by
91 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,318,843 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, FMR LLC, VR Adviser, LLC, COMMODORE CAPITAL LP, Fairmount Funds Management LLC, BlackRock Inc., 5AM Venture Management, LLC, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., and VANGUARD GROUP INC.
This page lists
91
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.